CTCBIO Inc. announced that it has received KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Kiwoom Securities Co., Ltd., Samsung Securities Co.,Ltd., KB Securities Co.,Ltd, Mirae Asset Daewoo Co., Ltd., Shinhan Investment Corp.
October 03, 2018
Share
On October 4, 2018, CTCBIO Inc. (KOSDAQ:A060590) closed the transaction.
CTCBIO Inc. is a Korea-based company engaged in the manufacture and marketing of pharmaceuticals, veterinary drugs, animal feed supplements and functional foods. It pharmaceuticals include anticancer agents, antibiotics, bone injury treatments, antiulcer agents, blood flow stimulants and others. Its veterinary drugs include vaccines, antibiotics, immune enhancers, enzymes, organic acid, avian influenza-related agents and others. Its animal feed supplements include pigments, kapok seed meal, sesame meal and others. Its functional food business includes the development and manufacture of enzymes, lactobacillus and related products mainly used in dairy products. It also involves in the development of pharmaceutical manufacturing technology and know-how. The Company distributes its products within domestic market and to overseas markets.
CTCBIO Inc. announced that it has received KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Kiwoom Securities Co., Ltd., Samsung Securities Co.,Ltd., KB Securities Co.,Ltd, Mirae Asset Daewoo Co., Ltd., Shinhan Investment Corp.
CTCBIO INC. 